Regulation of ABCB1 activity by microRNA-200c and microRNA-203a in breast cancer cells: the quest for microRNAs’ involvement in cancer drug resistance

Abstract

Aim: ABCB1 is a major player in cancer drug resistance. The purpose of this study was to functionally assess the regulation of ABCB1 activity in a doxorubicin-resistant breast cancer cell line by miR-200c and miR-203.

Methods: Human breast carcinoma cell lines MCF-7 (Doxorubicin-sensitive and not expressing ABCB1) and KCR (Doxorubicin-resistant and expressing ABCB1) were used to evaluate the expression levels of miR-200c and miR-203 by Real-time quantitative PCR (RT-qPCR). The effects of transient ectopic expression of miRNA-200c and miR-203 on the expression of ABCB1 in KCR and MCF-7 cells was verified by RT-qPCR and Western Blot. The extrusion activity of the ABCB1 pump was analyzed by fluorescence microscopy and flow cytometry through fluorescence substrate retention assays (DiOC₂) in the presence and absence of the ABCB1 inhibitor verapamil.

Results: RT-qPCR results indicated a 100,000-fold increase in ABCB1 mRNA expression levels in KCR cells compared to MCF-7 cells, and is inversely correlated with the expression of miR-203 and miR-200c. The insertion of miR-200c and miR-203 led to a higher retention of DiOC₂ within KCR cells, and slightly reduced the protein levels of ABCB1 in KCR cells, although the high initial expression of ABCB1 masked the reduction in protein levels. The increased intracellular accumulation of the fluorescent due DiOC₂ in the presence of the ABCB1 inhibitor verapamil correlated with the inhibition caused by miR-203 and miR-200c in transfected cells.

Conclusion: The present study demonstrates that miR-200c and miR-203 exert a negative modulating effect on the activity of ABCB1 associated with doxorubicin resistance.

Keywords

ABCB1 / drug resistance / drug extrusion / breast cancer / miR2003 / miR203

References

[1] Rueff J, Rodrigues AS, editors. Cancer Drug Resistance [Internet]. New York, NY: Springer New York; 2016 [cited 2017 May 2]. (Methods in Molecular Biology; vol. 1395). Available from: http://link.springer.com/10.1007/978-1-4939-3347-1 [Last accessed on 4 June 2019]

[2] Milani A.Overcoming endocrine resistance in metastatic breast cancer: Current evidence and future directions..World J Clin Oncol2014;5:990-1001 PMCID:PMC4259959

[3] Singh A.EMT, cancer stem cells and drug resistance: An emerging axis of evil in the war on cancer..Oncogene2010;29:4741-51 PMCID:PMC3176718

[4] Gomes BC,Rodrigues AS.MicroRNAs and cancer drug resistance..Methods Mol Biol2016;1395:137-62

[5] Gottesman MM.Mechanisms of cancer drug resistance..Annu Rev Med2002;53:615-27

[6] Atalay C,Gunduz U.Role of ABCB1 and ABCC1 Gene Induction on Survival in Locally Advanced Breast Cancer..J Chemother2008;20:734-9

[7] Gromicho M,Torres F,Fernandes AR.Instability of mRNA expression signatures of drug transporters in chronic myeloid leukemia patients resistant to imatinib..Oncol Rep2013;29:741-50

[8] Callaghan R,Bebawy M.Inhibition of the multidrug resistance P-glycoprotein: time for a change of strategy?.Drug Metab Dispos2014;42:623-31

[9] Gromicho M,Magalhaes M,Tavares P.Development of imatinib and dasatinib resistance: dynamics of expression of drug transporters ABCB1, ABCC1, ABCG2, MVP, and SLC22A1..Leuk Lymphoma.2011;52:1980-90

[10] Gottesman MM,Bates SE.Multidrug resistance in cancer: role of ATP-dependent transporters..Nat Rev Cancer2002;2:48-58

[11] Crowley E,Callaghan R.Zhou J.Generating Inhibitors of P-Glycoprotein: Where to, Now? BT - Multi-Drug Resistance in Cancer.2010;Totowa, NJHumana Press405-32

[12] Seiden MV.,Matulonis U,Rose P.A Phase II Study of the MDR Inhibitor Biricodar (INCEL, VX-710) and Paclitaxel in Women with Advanced Ovarian Cancer Refractory to Paclitaxel Therapy..Gynecol Oncol2002;86:302-10

[13] Chung FS,De Jesus MFM,See MFE.Disrupting P-glycoprotein function in clinical settings: what can we learn from the fundamental aspects of this transporter?.Am J Cancer Res2016;6:1583-98 PMCID:PMC5004065

[14] Duan Z,Seiden M V.Inhibition of ABCB1 (MDR1) and ABCB4 (MDR3) expression by small interfering RNA and reversal of paclitaxel resistance in human ovarian cancer cells..Mol Cancer Ther2004;3:833-8

[15] Haenisch S,Cascorbi I.MicroRNAs and their relevance to ABC transporters..Br J Clin Pharmacol2014;77:587-96 PMCID:PMC3971975

[16] Ikemura K,Okuda M.MicroRNAs as regulators of drug transporters, drug-metabolizing enzymes, and tight junctions: Implication for intestinal barrier function..Pharmacol Ther2014;143:217-24

[17] Riquelme I,Riffo-Campos A,Roa J.Emerging Role of miRNAs in the Drug Resistance of Gastric Cancer..Int J Mol Sci2016;17:424 PMCID:PMC4813275

[18] Katayama K,Sugimoto Y.Regulations of P-Glycoprotein/ABCB1/ MDR1 in Human Cancer Cells..New J Sci2014;

[19] Liang X-J,Zhao Y.Circumventing Tumor Resistance to Chemotherapy by Nanotechnology..Methods Mol Biol2010;596:467-88 PMCID:PMC3047496

[20] Tomono T,Ogihara T.Snail-Induced Epithelial-to-Mesenchymal Transition Enhances P-gp-Mediated Multidrug Resistance in HCC827 Cells..J Pharm Sci2017;106:2642-9

[21] Hamano R,Yamasaki M,Hara J.Overexpression of miR-200c induces chemoresistance in esophageal cancers mediated through activation of the Akt signaling pathway..Clin Cancer Res2011;17:3029-38

[22] Ma C,Ding YC,Wang Q.MicroRNA-200c overexpression inhibits chemoresistance, invasion and colony formation of human pancreatic cancer stem cells..Int J Clin Exp Pathol2015;8:6533-9 PMCID:PMC4525866

[23] Sui H,Pan SF,Wang YW.MiR200c attenuates P-gp-mediated MDR and metastasis by targeting JNK2/c-Jun signaling pathway in colorectal cancer..Mol Cancer Ther2014;13:3137-51

[24] Liu Y,Chen X,Mao C.Overexpression of miR-203 sensitizes paclitaxel (Taxol)-resistant colorectal cancer cells through targeting the salt-inducible kinase 2 (SIK2)..Tumour Biol2016;37:12231-9

[25] Ru P,Hsueh EC.Anti-miR-203 Upregulates SOCS3 Expression in Breast Cancer Cells and Enhances Cisplatin Chemosensitivity..Genes Cancer2011;2:720-7 PMCID:PMC3218409

[26] Drago-García D,Hernández-Lemus E.Network analysis of EMT and MET micro-RNA regulation in breast cancer..Sci Rep2017;7:13534 PMCID:PMC5648819

[27] Obayashi M,Tsunematsu T,Sasahira T.microRNA-203 suppresses invasion and epithelial-mesenchymal transition induction via targeting NUAK1 in head and neck cancer..Oncotarget2016;7:8223-39 PMCID:PMC4884988

[28] Taube JH,Lu E,Vijay V.Epigenetic silencing of microRNA-203 is required for EMT and cancer stem cell properties..Sci Rep2013;3:2687 PMCID:PMC3776231

[29] Gomes BC,Lopes P,Oliveira M.Prognostic value of microRNA-203a expression in breast cancer..Oncol Rep2016;36:1748-56

[30] Chen J,Cai H,Deng Y.Down-regulation of microRNA-200c is associated with drug resistance in human breast cancer..Med Oncol2012;29:2527-34

[31] Kars MD,Gündüz U,Arpaci F.Development of rational in vitro models for drug resistance in breast cancer and modulation of MDR by selected compounds..Anticancer Res2006;26:4559-68

[32] İşeri ÖD,Gündüz U,Chen X.Two different docetaxel resistant MCF-7 sublines exhibited different gene expression pattern..Mol Biol Rep2012;39:3505-16

[33] Işeri ÖD,Arpaci F,Pak I.Drug resistant MCF-7 cells exhibit epithelial-mesenchymal transition gene expression pattern..Biomed Pharmacother2011;65:40-5

[34] Armada A,Gonçalves LM,Custódio A.Generation of an antibody that recognizes Plasmodium chabaudi cysteine protease (chabaupain-1) in both sexual and asexual parasite life cycle and evaluation of chabaupain-1 vaccine potential..Exp Parasitol2013;135:166-74

[35] Armada A,Spengler G,Amaral L.Fluorimetric methods for analysis of permeability, drug transport kinetics, and inhibition of the ABCB1 membrane transporter..Methods Mol Biol2016;1395:87-103

[36] Gomes BC,Lopes P,Oliveira M.Prognostic value of microRNA-203a expression in breast cancer..Oncol Rep2016;36:1748-56

[37] Novo C,Prata S,Armada A.Gene sequencing, modelling and immunolocalization of the protein disulfide isomerase from Plasmodium chabaudi..Int J Biol Macromol2009;45:399-406

[38] Gromicho M,Magalhaes M,Tavares P.Development of imatinib and dasatinib resistance: dynamics of expression of drug transporters ABCB1, ABCC1, ABCG2, MVP, and SLC22A1..Leuk Lymphoma2011;52:1980-90

[39] Haenisch S,Cascorbi I.MicroRNAs and their relevance to ABC transporters..Br J Clin Pharmacol2014;77:587-96 PMCID:PMC3971975

[40] Liao H,Qiu S,Huang L.MiR-203 downregulation is responsible for chemoresistance in human glioblastoma by promoting epithelial-mesenchymal transition via SNAI2..Oncotarget2015;6:8914-28 PMCID:PMC4496192

[41] Zhou Y,Spizzo R,Mathur R.miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase..Mol Oncol2014;8:83-92 PMCID:PMC4124530

[42] LI T,ZHANG X-P.miR-203 enhances chemosensitivity to 5-fluorouracil by targeting thymidylate synthase in colorectal cancer..Oncol Rep2015;33:607-14

[43] Chang L,Wang Y,Huo B.MicroRNA-200c Regulates the Sensitivity of Chemotherapy of Gastric Cancer SGC7901/DDP Cells by Directly Targeting RhoE..Pathol Oncol Res2014;20:93-8

[44] Cittelly DM,Howe EN,Jean A.Restoration of miR-200c to ovarian cancer reduces tumor burden and increases sensitivity to paclitaxel..Mol Cancer Ther2012;11:2556-65 PMCID:PMC3519949

[45] Kopp F,Wagner E.Aboussekhra A.miR-200c sensitizes breast cancer cells to doxorubicin treatment by decreasing TrkB and Bmi1 expression..PLoS One2012;7:e50469 PMCID:PMC3510180

[46] Bai WD,Zhang MY,Xi WJ.MiR-200c suppresses TGF-beta signaling and counteracts trastuzumab resistance and metastasis by targeting ZNF217 and ZEB1 in breast cancer..Int J Cancer2014;135:1356-68

[47] Beck WT,Willman CL,Parham DM.Methods to detect P-glycoprotein-associated multidrug resistance in patients’ tumors: consensus recommendations..Cancer Res1996;56:3010-20

[48] Lebedeva IV,Patton WF.Sensitive and specific fluorescent probes for functional analysis of the three major types of Mammalian ABC transporters..PLoS One2011;6:e22429 PMCID:PMC3142157

[49] Katayama K,Ohnuma S,Swaim W.Revealing the fate of cell surface human P-glycoprotein (ABCB1): the Lysosomal Degradation Pathway HHS Public Access..Biochim Biophys Acta2015;1853:2361-70 PMCID:PMC4558211

[50] Jin HY,Miletic AV,Knight S.Transfection of microRNA mimics should be used with caution..Front Genet2015;6:340 PMCID:PMC4667072